Novel approaches to reduce restenosis

Rafael Beyar

Research output: Contribution to journalArticle

Abstract

Percutaneous coronary intervention (PCI) has become the major technique of revascularization and is replacing cardiac bypass surgery. PCI is typically performed today with a combination of balloon dilatation and stents, with some 80% of the procedures followed by stent implantation. After balloon dilatation, an acute recoil response can be responsible for some 30% immediate loss of the vessel lumen at the end of the procedure. Restenosis is the late loss (within 6-9 months) of the lumen of the artery due to vessel shrinkage (negative remodeling) and an intense proliferative response to the local injury. Stents reduce restenosis by 30% by preventing acute recoil and reducing long-term negative arterial remodeling. Yet, long-term pressure of the stent struts against the vessel wall stimulates an increased arterial proliferative response, which is the major cause for stent restenosis. Limiting the proliferative response by local radiation (brachytherapy) have reduced restenosis, at a cost of increased late thrombogenicity and delayed vessel healing. Drug-eluting stents have shown extremely promising results in limiting restenosis. Rapamycin and paclitaxel are the major drugs in eluting stents in clinical use today, having reduced restenosis to less than 10%. Local cellular and genetic therapy approaches are currently at preclinical phases. The future of percutaneous revascularization remains bright and will enhance the effectiveness of PCI as the primary revascularization therapy for coronary artery disease.

Original languageEnglish (US)
Pages (from-to)367-378
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume1015
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Stents
Percutaneous Coronary Intervention
Drug-Eluting Stents
Dilatation
Balloons
Brachytherapy
Sirolimus
Paclitaxel
Genetic Therapy
Thoracic Surgery
Coronary Artery Disease
Struts
Arteries
Vessel
Radiation
Pharmaceutical Preparations
Surgery
Pressure
Costs and Cost Analysis
Wounds and Injuries

Keywords

  • Arterial remodeling
  • Coronary restenosis
  • Noontime proliferation
  • Stents

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Novel approaches to reduce restenosis. / Beyar, Rafael.

In: Annals of the New York Academy of Sciences, Vol. 1015, 2004, p. 367-378.

Research output: Contribution to journalArticle

Beyar, Rafael. / Novel approaches to reduce restenosis. In: Annals of the New York Academy of Sciences. 2004 ; Vol. 1015. pp. 367-378.
@article{9081483770444bba89977ef8735049ec,
title = "Novel approaches to reduce restenosis",
abstract = "Percutaneous coronary intervention (PCI) has become the major technique of revascularization and is replacing cardiac bypass surgery. PCI is typically performed today with a combination of balloon dilatation and stents, with some 80{\%} of the procedures followed by stent implantation. After balloon dilatation, an acute recoil response can be responsible for some 30{\%} immediate loss of the vessel lumen at the end of the procedure. Restenosis is the late loss (within 6-9 months) of the lumen of the artery due to vessel shrinkage (negative remodeling) and an intense proliferative response to the local injury. Stents reduce restenosis by 30{\%} by preventing acute recoil and reducing long-term negative arterial remodeling. Yet, long-term pressure of the stent struts against the vessel wall stimulates an increased arterial proliferative response, which is the major cause for stent restenosis. Limiting the proliferative response by local radiation (brachytherapy) have reduced restenosis, at a cost of increased late thrombogenicity and delayed vessel healing. Drug-eluting stents have shown extremely promising results in limiting restenosis. Rapamycin and paclitaxel are the major drugs in eluting stents in clinical use today, having reduced restenosis to less than 10{\%}. Local cellular and genetic therapy approaches are currently at preclinical phases. The future of percutaneous revascularization remains bright and will enhance the effectiveness of PCI as the primary revascularization therapy for coronary artery disease.",
keywords = "Arterial remodeling, Coronary restenosis, Noontime proliferation, Stents",
author = "Rafael Beyar",
year = "2004",
doi = "10.1196/annals.1302.032",
language = "English (US)",
volume = "1015",
pages = "367--378",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Novel approaches to reduce restenosis

AU - Beyar, Rafael

PY - 2004

Y1 - 2004

N2 - Percutaneous coronary intervention (PCI) has become the major technique of revascularization and is replacing cardiac bypass surgery. PCI is typically performed today with a combination of balloon dilatation and stents, with some 80% of the procedures followed by stent implantation. After balloon dilatation, an acute recoil response can be responsible for some 30% immediate loss of the vessel lumen at the end of the procedure. Restenosis is the late loss (within 6-9 months) of the lumen of the artery due to vessel shrinkage (negative remodeling) and an intense proliferative response to the local injury. Stents reduce restenosis by 30% by preventing acute recoil and reducing long-term negative arterial remodeling. Yet, long-term pressure of the stent struts against the vessel wall stimulates an increased arterial proliferative response, which is the major cause for stent restenosis. Limiting the proliferative response by local radiation (brachytherapy) have reduced restenosis, at a cost of increased late thrombogenicity and delayed vessel healing. Drug-eluting stents have shown extremely promising results in limiting restenosis. Rapamycin and paclitaxel are the major drugs in eluting stents in clinical use today, having reduced restenosis to less than 10%. Local cellular and genetic therapy approaches are currently at preclinical phases. The future of percutaneous revascularization remains bright and will enhance the effectiveness of PCI as the primary revascularization therapy for coronary artery disease.

AB - Percutaneous coronary intervention (PCI) has become the major technique of revascularization and is replacing cardiac bypass surgery. PCI is typically performed today with a combination of balloon dilatation and stents, with some 80% of the procedures followed by stent implantation. After balloon dilatation, an acute recoil response can be responsible for some 30% immediate loss of the vessel lumen at the end of the procedure. Restenosis is the late loss (within 6-9 months) of the lumen of the artery due to vessel shrinkage (negative remodeling) and an intense proliferative response to the local injury. Stents reduce restenosis by 30% by preventing acute recoil and reducing long-term negative arterial remodeling. Yet, long-term pressure of the stent struts against the vessel wall stimulates an increased arterial proliferative response, which is the major cause for stent restenosis. Limiting the proliferative response by local radiation (brachytherapy) have reduced restenosis, at a cost of increased late thrombogenicity and delayed vessel healing. Drug-eluting stents have shown extremely promising results in limiting restenosis. Rapamycin and paclitaxel are the major drugs in eluting stents in clinical use today, having reduced restenosis to less than 10%. Local cellular and genetic therapy approaches are currently at preclinical phases. The future of percutaneous revascularization remains bright and will enhance the effectiveness of PCI as the primary revascularization therapy for coronary artery disease.

KW - Arterial remodeling

KW - Coronary restenosis

KW - Noontime proliferation

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=3042797865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042797865&partnerID=8YFLogxK

U2 - 10.1196/annals.1302.032

DO - 10.1196/annals.1302.032

M3 - Article

C2 - 15201175

AN - SCOPUS:3042797865

VL - 1015

SP - 367

EP - 378

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -